Fundraising FoxAlexandria — 2021 Investments
14 investments dated 2021 · listed companies and verified rows first · show all
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesForesite CapitalFrazier Life SciencesHercules Capital, Inc.+8 more
Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.
BiotechDeep TechDigital HealthMedical DevicesWatertown, US
Paul L. Berns(Chairman and Chief Executive Officer)Joshua Pinto(Executive Officer)Tamara Tompkins(Executive Officer)inKari Stefansson(Director)Maykin Ho(Director)Alaa Halawa(Director)
Co-investorsARCH Venture PartnersCatalio Capital Management, LPF-Prime CapitalK2 HealthVenturesMercury FundPremier Partners+12 more
Asher Bio is a biotechnology company developing targeted immunotherapies for cancer, autoimmune, and infectious diseases using a cis-targeting platform that selectively activates specific immune cell types.
BiotechHealthtechMedical DevicesSan Francisco, US
Ivana Djuretic(Founder)inAndy Yeung(Drug discovery)inYik Andy Yeung(Executive Officer, Director, Promoter)
Co-investorsThird Rock VenturesEmles Venture PartnersGoAhead VenturesMission Bay CapitalMission BiocapitalRA Capital+9 more
Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform.
BiotechHealthtechSan Diego, US
Vijaya Pattabiraman(Co-founder & Chief Technology Officer)inJeffrey Bode(Scientific co-founder)inFredrik Wiklund(Chief Executive Officer)Christine Siu(Director)Michael Rosenzweig(Director)Bertolt Kreft(Executive Officer)
Co-investorsRA CapitalJohnson & Johnson Innovation – JJDCVersant VenturesVenrockBlackRockFidelity Investments+2 more
Fountain is a biotech company developing first-in-class therapies for diseases and conditions caused by aging, using in vitro and in vivo screening platforms to identify drug candidates.
BiotechHealthtechLongevitySan Francisco, US
Thomas Rando(Co-founder)Joseph Rodgers(Co-founder)inTom Cheung(Co-founder)inTsang(Chief Business Officer)Thomas Rando, M.D. Ph.D.(Founder, Executive Chair of the Board)Joseph T Rodgers, Ph.D.(Co-Founder, Scientific and Technical Lead)
Co-investorsKhosla VenturesNan Fung Life SciencesR42 Group
Immunai develops AMICA, a data platform for decoding the immune system to accelerate drug discovery and development.
AI & Machine LearningBiotechData & InfrastructureNew York City, US
Luis Voloch(Founder)Noam Solomon(Founder)
Co-investorsCatalio Capital Management, LPGefen CapitalICON - Israel Collaboration NetworkKoch Disruptive TechnologiesMeron CapitalPerot Jain+3 more
IpiNovyx Bio is a biotech company developing potent and selective immunoproteasome inhibitors to treat cancer, autoimmune, and inflammatory diseases.
BiotechHealthtechMedical DevicesWest Nyack, US
Gang Lin(Scientific Founder)Carl Nathan(Scientific Founder)Franck Barrat(Scientific Founder)inMarc Appel(Executive Officer, Director)Lutz Giebel(Director)James Graham(Director)
Co-investorsPathway Bioventures
Kytopen develops non-viral gene delivery technology called Flowfect that combines fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP into cells for high-throughput transfection.
BiotechDeep TechHardwareCambridge, US
Cullen Buie(Founder; Board Observer)inPaulo Garcia(Founder)inMichael Chiu(Chief Executive Officer)in
BoardPaxton Major(Director)inAnn DeWitt(Director)inPaul Wotton(Director)
Co-investorsBantam GroupHorizons VenturesMassVenturesSelvedge VentureTBD AngelsTelegraph Hill Partners+2 more
Mnemo Therapeutics is a Paris-based clinical-stage biotech developing cell therapies using its EnfiniT epigenetic antigen discovery platform to target tumor-specific antigens for CAR-T therapies.
Co-investorsSofinnova PartnersCasdin CapitalREDMILE
CREATE Medicines develops in vivo CAR immunotherapy using proprietary mRNA-LNP technology to program T cells, NK cells, and myeloid cells directly within the body for cancer, autoimmunity, and fibrosis.
AI & Machine LearningBiotechHealthtechMedical DevicesCambridge, US
Daniel Getts, Ph.D.(Chief Executive Officer, Cofounder, Board Director)
Co-investorsARCH Venture Partners8VCHatteras Venture PartnersNewpath Partners
Boston-based biotech developing drugs against the 'dark genome'/repeatome for autoimmune disease, cancer and neurodegeneration.
Benjamin Greenbaum(Founder)David Ting(Founder)Rosana Kapeller(Founder)
Co-investorsAndreessen HorowitzARCH Venture PartnersGV (Google Ventures)Luma GroupSanofi VenturesAbingworth+11 more
Umoja Biopharma develops in vivo CAR T cell cancer therapies using its VivoVec platform, which generates chimeric antigen receptor T cells directly inside a patient's body rather than through the traditional ex vivo process.
BiotechHealthtechSeattle, US
Andrew M. Scharenberg(Executive Officer, Director)Philip S. Low(Director)Andrew Scharenberg(Founder)Michael Jensen(Founder)Philip Low(Founder)Ryan Crisman(Founder)
Co-investorsMPM BioImpactDCVC BioQiming Venture Partners USASoftBank GroupK2 HealthVenturesSoftBank Vision Fund+2 more
Developing novel treatments based on the 12-LOX pathway for immuno-inflammatory diseases.
Co-investorsAlumni VenturesHatteras Venture PartnersPappas CapitalSanofi VenturesGenesys CapitalJDRF T1D Fund+4 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.